- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04821973
Respiratory Tele Monitoring COVID 19 (TMR COVID-19)
Interest of Respiratory Tele Monitoring in COVID-19 Pneumonia
The determinants of the evolution to a severe form for COVID-19 pneumonia remain unclear. COVID-19 pneumonia is characterized by a hypoxemia with a possible rapid worsening and related resuscitation requirement. The monitoring of patients in hospital wards (excluding intensive care unit) is therefore both necessary and complicated given the contagious risks for health workers.
The COVID 19 Respiratory Tele Monitoring (RTM COVID 19) research project is based on a comparison between usual nurse respiratory monitoring (4 to 6 time per day) of respiratory parameters (capillary oxygen saturation, respiratory rate, hearth rate) and a continuous monitoring of these respiratory parameters with continuous monitoring by a portable, wireless and stand-alone device.
The main objective of this work is a more sensitive and earlier detection of respiratory degradation events in patients with COVID-19 pneumonia (capillary desaturation, increased respiratory rate) requiring the introduction of oxygen therapy, its increase or a resuscitation requirement with possible intensive care admission.
A prospective, randomized, multicentre, comparative exposure study will be conducted with planned inclusion of 80 patients. This investigation will focus on patients with COVID-19 pneumonia hospitalized in dedicated medical wards of two University Hospitals in France.
A randomization will be stratified by Hospital and adapted so that each Hospital provides the same number of subjects in each arms:
- Control Respiratory Monitoring Group (40 patients)
- Experimental Respiratory Monitoring Group (40 patients)
The main criterion is respiratory degradation event, during a 4 days period after ward admission, which motivates a change in the therapeutic strategy defined by the presence of at least one of these elements:
- Capillary saturation < 94% (regardless of oxygen intake) for at least 2 minutes.
- And/or an increase in respiratory rate > 20/minute for at least 2 minutes.
The modification of the therapeutic strategy is defined by:
- Introduction of oxygen therapy for included patients without oxygen therapy or supplementation of oxygen therapy > 2 litres/minutes for included patients with oxygen therapy
- And/or introduction of a high oxygen concentration mask
- And/or Request an On-Site Opinion from a member of the resuscitation team.
- And/or Transfer to intensive care or resuscitation unit
- And/or Need for immediate resuscitation for life-threatening distress.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pierre MICHELET
- Phone Number: +33 04 13 42 97 05
- Email: pierre.michelet@ap-hm.fr
Study Contact Backup
- Name: Claire MORANDO
- Phone Number: +33 0491382183
- Email: claire.morando@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13005
- Recruiting
- Assistance Publique Hopitaux de Marseille
-
Contact:
- Pierre MICHELET
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with COVID 19 pneumonia assessed by PCR and CT scann.
- Patient admited in a dedicated medical ward
- Patient with oxygen supply less or equal to 4 liters per minute.
- Written informed consent
Exclusion Criteria:
- Patient with limitation of care.
- Patient with immediate risk to ICU transfer within the first 12 hours
- Patient with neurological or psychiatric symptoms that interfere with respiratory parameters interpretation.
- Patient with acute or chronic respiratory disease such as COPD, cancer.
- Pregnancy, age < 18 of vulnerable profile.
- Patient refusal to participate or previously included in a clinical research trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Control Respiratory Monitoring Group
|
usual nurse respiratory monitoring
|
EXPERIMENTAL: Experimental Respiratory Monitoring Group
|
continuous monitoring by a portable, wireless and stand-alone device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
respiratory degradation event 1
Time Frame: during the 4 days period
|
Capillary saturation < 94% (regardless of oxygen intake) for at least 2 minutes
|
during the 4 days period
|
respiratory degradation event 2
Time Frame: during the 4 days period
|
an increase in respiratory rate > 20/minute for at least 2 minutes
|
during the 4 days period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
New Early Warning Score (NEWS) evaluation
Time Frame: during the 4 days period
|
post hoc comparison of the respiratory monitoring using the experimental device with the NEWS on the repiratory event occurence
|
during the 4 days period
|
Assessment of caregiver feelings
Time Frame: during the 4 days period
|
post hoc analysis of the team in regard to the monitoring strategy used based on a self-assessment questionnaire
|
during the 4 days period
|
Intensive Care Unit tansfer
Time Frame: during the 4 days period
|
post hoc analysis of the frequency of ICU transfer
|
during the 4 days period
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-35
- 2020-A01627-32 (REGISTRY: IDRCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on usual monitoring
-
Novartis PharmaceuticalsCompleted
-
VA Office of Research and DevelopmentCompletedStress Disorders, Post-TraumaticUnited States
-
Radboud University Medical CenterNot yet recruitingTelemedicine | eHealth | Wheezing
-
Massachusetts General HospitalNot yet recruitingPreeclampsia | Hypertension in Pregnancy | Gestational Hypertension | Chronic Hypertension With Pre-Eclampsia | Hypertension Complicating Pregnancy, Childbirth, and the Puerperium
-
VA Palo Alto Health Care SystemVA Puget Sound Health Care System; Durham VA Medical CenterCompletedStress Disorders, Post-TraumaticUnited States
-
The University of Texas Health Science Center at...National Center for Advancing Translational Sciences (NCATS)CompletedHypertensionUnited States
-
University of Alabama at BirminghamNational Institute on Minority Health and Health Disparities (NIMHD)Not yet recruiting
-
Sheba Medical CenterCompleted
-
Tehran University of Medical SciencesResearch Center for Rational Use of DrugsCompletedHypertensionIran, Islamic Republic of
-
Institute for Bioengineering of CataloniaRecruitingSpasticity, Muscle | Stroke, Acute | Motor Disorders | Hemiparesis;Poststroke/CVASpain